PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 3282657-0 1988 [Extracardiovascular effects of nifedipine in the treatment of hypertensive patients: glucose tolerance and behavior of immunoreactive insulin]. Nifedipine 32-42 insulin Homo sapiens 135-142 3280492-10 1988 However, nifedipine, verapamil, and diltiazem in high doses may inhibit liberation of insulin. Nifedipine 9-19 insulin Homo sapiens 86-93 2718503-1 1989 This case report describes a 60-year-old diabetic patient whose daily insulin requirements increased by 30 percent following nifedipine administration. Nifedipine 125-135 insulin Homo sapiens 70-77 2654199-6 1989 Nifedipine produced a tendency towards an increase in glucagon release and a reduction in insulin release although these changes did not reach statistical significance. Nifedipine 0-10 insulin Homo sapiens 90-97 2663524-0 1989 Insulin secretion and glucose tolerance in non-insulin dependent diabetic patients after chronic nifedipine treatment. Nifedipine 97-107 insulin Homo sapiens 0-7 2663524-0 1989 Insulin secretion and glucose tolerance in non-insulin dependent diabetic patients after chronic nifedipine treatment. Nifedipine 97-107 insulin Homo sapiens 47-54 2651487-6 1989 Nifedipine produced a tendency toward an increase in glucagon release and a reduction in insulin release although these changes did not reach statistical significance. Nifedipine 0-10 insulin Homo sapiens 89-96 3100863-2 1986 Three weeks following the administration of nifedipine, both glucose and insulin concentrations decreased significantly from 102.1 +/- 2.6 to 94.9 +/- 2.2 mg/dl and from 19.9 +/- 2.9 to 13.9 +/- 1.7 microU/ml and also remained significantly lower after 9 weeks of nifedipine therapy. Nifedipine 44-54 insulin Homo sapiens 73-80 3100863-8 1986 Our data indicate that nifedipine lowers serum glucose values despite decreased insulin and constant glucagon levels in hypertensive hemodialyzed patients. Nifedipine 23-33 insulin Homo sapiens 80-87 3896885-7 1985 However, basal insulin levels were reduced by 3 month-administration of nifedipine (from 19 +/- 2 micromicrons/ml to 10 +/- 1 micromicrons/ml, p = 0,01). Nifedipine 72-82 insulin Homo sapiens 15-22 3019137-4 1986 Nifedipine, a calcium channel blocker, inhibits insulin, but not phorbol stimulated PDE. Nifedipine 0-10 insulin Homo sapiens 48-55 7000443-1 1980 The effect of the acute and long-term oral administration of nifedipine on glucose and insulin levels during a standard oral glucose tolerance test was studied in a total of 8 diabetic and 8 non-diabetic patients. Nifedipine 61-71 insulin Homo sapiens 87-94 10923530-9 1998 The effect of nifedipine on insulin sensitivity is lower than that of amlodipine and perindopril. Nifedipine 14-24 insulin Homo sapiens 28-35 24786779-3 2014 In the first study, we investigated the effects of a 3-month treatment with an ARB with additional PPARgamma agonist activity, telmisartan, or with a dihydropyridine calcium channel blocker, nifedipine, on insulin signalling in patients with mild-moderate essential hypertension. Nifedipine 191-201 insulin Homo sapiens 206-213 22775778-5 2012 RESULTS: OSA -induced insulin secretion from mouse islets and MIN6 beta-cells was inhibited by nifedipine, a voltage-gated Ca(2+) channel blocker, and by the removal of extracellular Ca(2+), respectively. Nifedipine 96-106 insulin Homo sapiens 23-30 18288073-1 2008 The aim of this paper was to describe a case of massive atenol and nifedipine poisoning, complicated by the co-existence of liver cirrhosis, where standard therapies (fluid replacement, vasopressors and inotropic agents, insulin, glucagon, calcium and bowel decontamination) were ineffective in restoring an adequate heart rate, blood pressure, renal and intestinal blood flow. Nifedipine 67-77 insulin Homo sapiens 221-228 15550513-8 2005 The simultaneous decrease in both insulin release and glucose-6-phosphate dehydrogenase activity induced by blocking the autocrine insulin effect with three different procedures (blockage of insulin release by nifedipine, immune neutralization of the released insulin by antiinsulin serum, and blockage of an insulin intracellular effector such as phosphotidylinositol 3-kinase by wortmannin) strongly suggests a physiological role of sperm insulin on these two events. Nifedipine 210-220 insulin Homo sapiens 131-138 15283694-7 2004 Insulin-induced Ca(2+) increase was blocked in Ca(2+)-free medium and by either nifedipine or ryanodine. Nifedipine 80-90 insulin Homo sapiens 0-7 12441210-0 2002 Improvement of insulin sensitivity by a long-acting nifedipine preparation (nifedipine-CR) in patients with essential hypertension. Nifedipine 52-62 insulin Homo sapiens 15-22 12441210-2 2002 But recently a controlled-released formulation of nifedipine (nifedipine-GITS) has been reported that it could improve insulin sensitivity. Nifedipine 50-60 insulin Homo sapiens 119-126 12441210-2 2002 But recently a controlled-released formulation of nifedipine (nifedipine-GITS) has been reported that it could improve insulin sensitivity. Nifedipine 62-72 insulin Homo sapiens 119-126 12441210-7 2002 CONCLUSIONS: Our results indicate that the long-acting nifedipine (nifedipine-CR) is associated with improved insulin sensitivity. Nifedipine 55-65 insulin Homo sapiens 110-117 7002569-3 1980 10 subjects had normal glucose tolerance; in them nifedipine administration reduced the insulin response to oral glucose in the first 60 min, but improved glucose tolerance. Nifedipine 50-60 insulin Homo sapiens 88-95 28600547-4 2017 ABCC8-deficient insulin-producing cells secreted higher insulin than their wild-type counterparts, and the excess insulin secretion was rescued by nifedipine, octreotide and nicorandil. Nifedipine 147-157 insulin Homo sapiens 16-23 26849821-2 2016 The calcium channel blocker nifedipine is reported to ameliorate insulin resistance possibly by activating PPARgamma. Nifedipine 28-38 insulin Homo sapiens 65-72 24786779-10 2014 In conclusion, telmisartan and nifedipine are both effective in improving insulin signalling in human hypertension; however, telmisartan seems to have broader effects. Nifedipine 31-41 insulin Homo sapiens 74-81 17544393-8 2007 Intracellular oxidative stress was also increased by insulin stimulation in a dose-dependent manner (0.01-10 microM), and 0.1 microM azelnidipine was found to block intracellular reactive oxygen species production more effectively than 0.1 microM nifedipine. Nifedipine 247-257 insulin Homo sapiens 53-60 15550513-8 2005 The simultaneous decrease in both insulin release and glucose-6-phosphate dehydrogenase activity induced by blocking the autocrine insulin effect with three different procedures (blockage of insulin release by nifedipine, immune neutralization of the released insulin by antiinsulin serum, and blockage of an insulin intracellular effector such as phosphotidylinositol 3-kinase by wortmannin) strongly suggests a physiological role of sperm insulin on these two events. Nifedipine 210-220 insulin Homo sapiens 131-138 15550513-8 2005 The simultaneous decrease in both insulin release and glucose-6-phosphate dehydrogenase activity induced by blocking the autocrine insulin effect with three different procedures (blockage of insulin release by nifedipine, immune neutralization of the released insulin by antiinsulin serum, and blockage of an insulin intracellular effector such as phosphotidylinositol 3-kinase by wortmannin) strongly suggests a physiological role of sperm insulin on these two events. Nifedipine 210-220 insulin Homo sapiens 131-138 15550513-8 2005 The simultaneous decrease in both insulin release and glucose-6-phosphate dehydrogenase activity induced by blocking the autocrine insulin effect with three different procedures (blockage of insulin release by nifedipine, immune neutralization of the released insulin by antiinsulin serum, and blockage of an insulin intracellular effector such as phosphotidylinositol 3-kinase by wortmannin) strongly suggests a physiological role of sperm insulin on these two events. Nifedipine 210-220 insulin Homo sapiens 131-138 15550513-8 2005 The simultaneous decrease in both insulin release and glucose-6-phosphate dehydrogenase activity induced by blocking the autocrine insulin effect with three different procedures (blockage of insulin release by nifedipine, immune neutralization of the released insulin by antiinsulin serum, and blockage of an insulin intracellular effector such as phosphotidylinositol 3-kinase by wortmannin) strongly suggests a physiological role of sperm insulin on these two events. Nifedipine 210-220 insulin Homo sapiens 131-138 8415207-5 1993 These results prove that in non-diabetic patients nifedipine reduces the early response of the B-cells to glucose, but this effect is partly compensated by decreased insulin uptake by the liver. Nifedipine 50-60 insulin Homo sapiens 166-173 9436865-5 1998 Calcium antagonism with nifedipine abolished the ethanol augmentation of insulin secretion (insulin area 0-20 min, ethanol vs. combination, p < 0.05; and C-peptide area 0-20 min, ethanol vs. combination, p < 0.01). Nifedipine 24-34 insulin Homo sapiens 73-80 7789631-7 1995 Insulin-mediated glucose uptake (144 +/- 11 mg.m-2.min-1), glucose oxidation (76 +/- 4 mg.m-2.min-1), and nonoxidative glucose disposal (71 +/- 6 mg.m-2.min-1) were similar in all groups before the start of antihypertensive treatment and did not change in captopril and nifedipine groups. Nifedipine 270-280 insulin Homo sapiens 0-7 7752176-6 1995 Insulin sensitivity on the other hand was significantly impaired by nifedipine treatment only (-1.6 mg/kg/min, P < 0.01). Nifedipine 68-78 insulin Homo sapiens 0-7 7752176-8 1995 The insignificant change in heart rate induced by nifedipine treatment correlated with the change in HbA1c (r = 0.50, P = 0.05) and was inversely related to the change in insulin sensitivity (r = -0.56, P < 0.05). Nifedipine 50-60 insulin Homo sapiens 171-178 9283804-0 1997 Insulin responses to oral glucose during 4-year treatment with nifedipine retard in hypertensive patients with and without NIDDM. Nifedipine 63-73 insulin Homo sapiens 0-7 9194505-8 1997 Although in HT treated with nifedipine-retard, AUC of insulin (P < .01) and AUC of blood glucose levels (P < .05) decreased significantly after 1 year of treatment, triglyceride and total cholesterol levels did not decrease throughout the 5 years. Nifedipine 28-38 insulin Homo sapiens 54-61 8305165-0 1993 Effects of magnesium and nifedipine infusions on insulin action, substrate oxidation, and blood pressure in aged hypertensive patients. Nifedipine 25-35 insulin Homo sapiens 49-56 8305165-5 1993 Infusion of insulin and nifedipine v insulin alone reduced insulin-mediated increase in intracellular calcium (5.4 +/- 0.3 v 6.2 +/- 0.4 mumol/L, P < .02), but potentiated the insulin effect upon nonoxidative glucose (15.4 +/- 0.4 v 11.1 +/- 0.3 mumol/kg lean body mass [LBM] x min, P < .03) metabolism. Nifedipine 24-34 insulin Homo sapiens 37-44 8305165-5 1993 Infusion of insulin and nifedipine v insulin alone reduced insulin-mediated increase in intracellular calcium (5.4 +/- 0.3 v 6.2 +/- 0.4 mumol/L, P < .02), but potentiated the insulin effect upon nonoxidative glucose (15.4 +/- 0.4 v 11.1 +/- 0.3 mumol/kg lean body mass [LBM] x min, P < .03) metabolism. Nifedipine 24-34 insulin Homo sapiens 37-44 8305165-5 1993 Infusion of insulin and nifedipine v insulin alone reduced insulin-mediated increase in intracellular calcium (5.4 +/- 0.3 v 6.2 +/- 0.4 mumol/L, P < .02), but potentiated the insulin effect upon nonoxidative glucose (15.4 +/- 0.4 v 11.1 +/- 0.3 mumol/kg lean body mass [LBM] x min, P < .03) metabolism. Nifedipine 24-34 insulin Homo sapiens 37-44 8415207-9 1993 CONCLUSION: nifedipine, captopril, prazosin have a small influence on secretory function of pancreatic B-cells and may be recommended for the treatment of hypertension in patients with type 2 (non-insulin-dependent) diabetes. Nifedipine 12-22 insulin Homo sapiens 197-204 2043298-8 1991 This conclusion was supported in that measurement of insulin-stimulated glucose disposal showed a decrease in atenolol-treated patients and an increase in nifedipine-treated patients. Nifedipine 155-165 insulin Homo sapiens 53-60 7712685-8 1993 We therefore conclude, that long-term use of nifedipine increases UAER in normotensive microalbuminuric insulin-dependent subjects, in contrast to captopril or placebo. Nifedipine 45-55 insulin Homo sapiens 104-111 1956211-0 1991 Effect of nifedipine and nitrendipine on insulin release in non-diabetic obese patients: a double-blind, placebo-controlled study. Nifedipine 10-20 insulin Homo sapiens 41-48 1375175-5 1992 Insulin release induced by these secretagogues is enhanced by the dihydropyridine Ca2+ channel agonist BAYk8644 and depressed by the dihydropyridine Ca(2+)-channel antagonist nifedipine. Nifedipine 175-185 insulin Homo sapiens 0-7 1375175-9 1992 In most cells, the Ca2+ currents are enhanced by BAYk8644 and depressed by nifedipine at concentrations that have parallel effects on secretagogue-induced increases in cytosolic Ca2+ and insulin secretion. Nifedipine 75-85 insulin Homo sapiens 187-194 2043298-6 1991 In contrast, nifedipine-treated patients had similar plasma insulin, but lower plasma glucose and triglyceride concentrations after four months of therapy. Nifedipine 13-23 insulin Homo sapiens 60-67 2043298-7 1991 The changes in day-long plasma glucose and insulin responses suggested that resistance to insulin-stimulated glucose uptake had increased in association with atenolol treatment and decreased following nifedipine. Nifedipine 201-211 insulin Homo sapiens 90-97 2128281-4 1990 It is suggested that nifedipine-induced hyperglycaemia was not related to pancreatic effect and might be attributed to extra pancreatic mechanism by preventing the action of insulin in the tissues. Nifedipine 21-31 insulin Homo sapiens 174-181 1761067-0 1991 Effect of nifedipine on glucose potentiation of the acute insulin response to arginine in non-insulin-dependent diabetics. Nifedipine 10-20 insulin Homo sapiens 58-65 1761067-1 1991 The effect of 7-days of nifedipine treatment on insulin secretion has been analyzed in hypertensive patients with non-insulin-dependent mellitus (NIDDM). Nifedipine 24-34 insulin Homo sapiens 48-55 1761067-7 1991 Thus, nifedipine may impair insulin secretion at high glucose levels in patients with NiDDM. Nifedipine 6-16 insulin Homo sapiens 28-35 1723467-6 1991 However, a slight decrease in early insulin response to glucose was observed in the nifedipine and the nitrendipine groups. Nifedipine 84-94 insulin Homo sapiens 36-43 1725004-8 1991 In the nifedipine group, the fasting insulin level was decreased and the glucose/insulin ratio was significantly increased, suggesting an improvement in insulin sensitivity; moreover, total plasma cholesterol was significantly reduced. Nifedipine 7-17 insulin Homo sapiens 37-44 1725004-8 1991 In the nifedipine group, the fasting insulin level was decreased and the glucose/insulin ratio was significantly increased, suggesting an improvement in insulin sensitivity; moreover, total plasma cholesterol was significantly reduced. Nifedipine 7-17 insulin Homo sapiens 81-88 1725004-8 1991 In the nifedipine group, the fasting insulin level was decreased and the glucose/insulin ratio was significantly increased, suggesting an improvement in insulin sensitivity; moreover, total plasma cholesterol was significantly reduced. Nifedipine 7-17 insulin Homo sapiens 81-88 1725004-10 1991 Nifedipine can ameliorate insulin resistance and the lipid state. Nifedipine 0-10 insulin Homo sapiens 26-33